D Jeffrey Keyser insider trades: Lantern Pharma (LTRN) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where D reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | LTRN | ↑ Buy | 48,544 | $2.06 | $100K | Direct | May 14, 2026 (2d) |
| Jun 11, 2020 | LTRN | ↑ Buy | 10,000 | $15.00 | $150K | Direct | Jun 15, 2020 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LTRN insiders
Open-market trades in the last 12 months
About D Jeffrey Keyser's insider trades
D Jeffrey Keyser is a director at Lantern Pharma (LTRN). Since Jun 11, 2020, D has reported 2 open-market purchases worth $250K and no sales on SEC Form 4. In the last 12 months: 1 buy ($100K).
Their filings also include grants and awards (8 filings), other transactions (3 filings), option exercises (2 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LTRN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.